Indian J Pharm Close
 

Table 3: Mean (CV%) pharmacokinetic parameters after 2-, 4-, or 8-hour continuous intravenous infusion of ascending doses of rigosertib in patients with advanced cancer, by dose group

Table 3: Mean (CV%) pharmacokinetic parameters after 2-, 4-, or 8-hour continuous intravenous infusion of ascending doses of rigosertib in patients with advanced cancer, by dose group